Company needs to increase sales. That's not a criticism, I think...

Company needs to increase sales. That's not a criticism, I think they're doing a fine job for a new and small player in a market dominated by very large players. The fact that they've got a new, IP-protected and unique product works against them in a way, because it takes time to convince surgeons to leave their known products in favour of the untried one, no matter how much good data there is to support the move. This is what the distributor deal in USA has just started to do

Osteopore has proven excellent surgical outcomes. Their production costs are cheaper. Their supply chain is more reliable. And most importantly for surgeons, their products can be tailored quickly to meet the individual needs of patients. Added to all that, they have a pipeline of products and opportunities such as the entry into long-bone products that they've just signed up with QUT to research and develop, and the scope for dental.

The shift to Osteopore products will happen. But it will take time. That's cold comfort to shareholders who want good, fast results. But it's a reminder that sustainable growth doesn't happen quickly on the back of a press release. Also remember that the share price is three times the listing price, without any significant financial results. I got caught up in the hype when this company floated and bought in way too early. I regret that moment when emotion trumped reason, but I don't doubt the company or its ability to be a huge money-maker. In time.